Related Experiment Video
Updated: Dec 21, 2025

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks
Wen-Fa Zhang1, Preyesh Stephen1,2, Jean-François Thériault1
1Axe Molecular Endocrinology and Nephrology, CHU Research Center and Laval University, Québec City, Québec G1 V 4G2, Canada.
Abstract:
The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs represent a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNA-polymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome SARS-CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9%-98.1%) and lower identity among their Spike proteins (27%-77%). Thus, a 3D structural model of RdRp, NiRAN, non-structural protein 7 (nsp7), and nsp8 of SARS-CoV-2 was generated by modeling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirms their efficacy to inhibit viral RNA replication and provides an insight into their structure-based rational optimization for SARS-CoV-2 inhibition.
Insights
Understanding SARS-CoV-2 RNA-dependent-RNA-polymerase (RdRp) is crucial for combating the pandemic. This study models SARS-CoV-2 RdRp and shows how inhibitors like Galidesivir bind, aiding drug development.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Coronaviruses (CoVs), including SARS-CoV-2, pose a continuous global health threat due to their high contagiousness.
- RNA-dependent-RNA-polymerase (RdRp) is essential for viral replication, making it a key target for antiviral therapies.
- SARS-CoV-2 RdRp and NiRAN show high sequence identity (98.1% and 93.2%) with SARS-CoV, suggesting conserved structural and functional properties.
Purpose of the Study:
- To generate a 3D structural model of SARS-CoV-2 RdRp, NiRAN, nsp7, and nsp8.
- To investigate the binding interactions of known RdRp inhibitors (Galidesivir, Favipiravir, Penciclovir) with the SARS-CoV-2 RdRp.
- To provide insights for structure-based optimization of antiviral drugs against SARS-CoV-2.
Main Methods:
- Comparative sequence alignment of RdRp and Spike proteins across six coronaviruses.
- 3D structural modeling of SARS-CoV-2 RdRp, NiRAN, nsp7, and nsp8 based on SARS-CoV structures.
- Molecular docking simulations to analyze the binding poses and interactions of three antiviral inhibitors.
Main Results:
- High sequence identity observed between SARS-CoV-2 and SARS-CoV RdRp (98.1%) and NiRAN (93.2%).
- A 3D structural model of key SARS-CoV-2 replication proteins was successfully generated.
- Binding poses of Galidesivir, Favipiravir, and Penciclovir were elucidated, demonstrating their potential to inhibit viral RNA replication.
Conclusions:
- The structural model and inhibitor binding analysis provide a foundation for developing effective SARS-CoV-2 antiviral strategies.
- The conserved nature of RdRp across coronaviruses highlights its potential as a broad-spectrum antiviral target.
- Structure-based drug design can be effectively employed to optimize existing inhibitors and discover new ones for SARS-CoV-2.
Related Concept Videos
Viruses with RNA Genomes
Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
Leaky Scanning
Eukaryotic RNA Polymerases
All three eukaryotic RNAPs require specific transcription factors, of which the...
Viral Mutations
Size and Structure of Viral Genomes

